OR WAIT null SECS
Catalent invests $34 million to add a 2 x 2000-L single-use bioreactor system and laboratory space in Madison, WI.
Catalent Pharma Solutions has initiated a $34 million extension to its Madison, WI biologics manufacturing facility, a 22,000 sq.-ft.-expansion that will accommodate a 2 x 2000-L single-use bioreactor system for late-phase clinical and commercial production of up to 4000-L batches. The new footprint will also support expansion of analytical and process development laboratories, as well as office space, the company reported at an Oct. 21, 2016 ground-breaking ceremony.
The Wisconsin Economic Development Corporation has awarded Catalent with up to $1 million in state tax credits over the next three years. The actual amount of credits the company will receive is contingent upon the level of capital investment in Madison during the three-year period. The site that will eventually create more than 100 new jobs, Catalent reports.
The facility provides development, manufacturing, and analytical services for new biological entities (NBEs) and biosimilars and houses the company’s proprietary GPEx cell line technology, which is used to create high-yielding mammalian cell lines.
Opened in April 2013, the Madison facility was designed for cGMP production from 10-L to 1000-L scale, and non-GMP production up to 250-L scale using single-use technologies. Manufacturing is supported by analytical, process, and formulation development capabilities and separate microbiology and quality control functions.